MA71748A - Procédé sûr et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il12/il23 - Google Patents

Procédé sûr et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il12/il23

Info

Publication number
MA71748A
MA71748A MA71748A MA71748A MA71748A MA 71748 A MA71748 A MA 71748A MA 71748 A MA71748 A MA 71748A MA 71748 A MA71748 A MA 71748A MA 71748 A MA71748 A MA 71748A
Authority
MA
Morocco
Prior art keywords
antibody
safe
ulcerative colitis
effective method
treating ulcerative
Prior art date
Application number
MA71748A
Other languages
English (en)
Inventor
Christopher O'brien
Omoniyi ADEDOKUN
Jewel JOHANNS
Katherine Li
Colleen MARANO
Richard Strauss
Hongyan Zhang
Kimberly SHIELDS-TUTTLE
Original Assignee
Janssen Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech, Inc. filed Critical Janssen Biotech, Inc.
Publication of MA71748A publication Critical patent/MA71748A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MA71748A 2019-10-18 2020-10-16 Procédé sûr et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il12/il23 MA71748A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962916984P 2019-10-18 2019-10-18
EP24175051.2A EP4424381A3 (fr) 2019-10-18 2020-10-16 Procédé sûr et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il12/il23

Publications (1)

Publication Number Publication Date
MA71748A true MA71748A (fr) 2025-05-30

Family

ID=75492171

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71748A MA71748A (fr) 2019-10-18 2020-10-16 Procédé sûr et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il12/il23

Country Status (12)

Country Link
US (2) US20210115129A1 (fr)
EP (2) EP4045085A4 (fr)
JP (1) JP2022552548A (fr)
KR (1) KR20220084111A (fr)
CN (1) CN114555120A (fr)
AU (1) AU2020365589A1 (fr)
BR (1) BR112022007314A2 (fr)
CA (1) CA3158202A1 (fr)
IL (1) IL292215A (fr)
MA (1) MA71748A (fr)
MX (1) MX2022004581A (fr)
WO (1) WO2021074897A2 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11643460B2 (en) * 2014-10-28 2023-05-09 Staley Brod Administration of an anti-interleukin 12/23 antibody for treatment of autoimmune disease
JP6909208B2 (ja) * 2015-09-17 2021-07-28 アムジェン インコーポレイテッド Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
CN105294863B (zh) * 2015-11-13 2019-01-22 叶才果 双功能抗体及其用途
AU2017376807B2 (en) * 2016-12-14 2024-07-18 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with an IL-12/IL-23 inhibitor released using an ingestible device
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019106206A1 (fr) * 2017-12-01 2019-06-06 Fyb 202 Project Gmbh Formulations liquides stables, à faible viscosité et à haute concentration en un anticorps anti-il-12/23p40
CZ38255U1 (cs) * 2018-09-24 2024-11-20 Janssen Biotech, Inc Protilátka proti IL-12/IL-23p40 pro použití při způsobu léčení středně až závažně aktivní vředové kolitidy

Also Published As

Publication number Publication date
WO2021074897A2 (fr) 2021-04-22
IL292215A (en) 2022-06-01
KR20220084111A (ko) 2022-06-21
MX2022004581A (es) 2022-10-07
EP4045085A4 (fr) 2023-11-15
US20210115129A1 (en) 2021-04-22
BR112022007314A2 (pt) 2022-09-20
US20240294625A1 (en) 2024-09-05
EP4424381A2 (fr) 2024-09-04
CA3158202A1 (fr) 2021-04-22
CN114555120A (zh) 2022-05-27
WO2021074897A3 (fr) 2021-05-27
EP4045085A2 (fr) 2022-08-24
EP4424381A3 (fr) 2024-11-13
JP2022552548A (ja) 2022-12-16
AU2020365589A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
EP3883606A4 (fr) Méthode sûre et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il12/il23
MA50666A (fr) Méthode sûre et efficace de traitement de lupus avec un anticorps anti-il12/il23
MA46366A (fr) Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique contre l'il-23
EP3724794A4 (fr) Système et procédé de simulation de modèles de réservoir
EP3648725A4 (fr) Système et procédé d'évaluation de l'ajustement d'un exosquelette
EP3499838A4 (fr) Procédé de traitement de session et dispositif associé
EP3318899A4 (fr) Capteur sismique et procédé de détermination de séisme
EP3808542A4 (fr) Dispositif arithmétique, système de détection, appareil de modélisation, procédé arithmétique, procédé de détection, procédé de modélisation, programme arithmétique, programme de détection et programme de modélisation
EP3498387A4 (fr) Appareil et procédé de traitement de cendres incinérées
EP3883607A4 (fr) Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
EP3885956A4 (fr) Procédé et dispositif de traitement de transaction
MA50580A (fr) Méthode sûre et efficace de traitement de l'arthrite psoriasique par un anticorps spécifique anti-il23
EP3541422A4 (fr) Procédé de traitement du psoriasis avec un anticorps anti-il-23 spécifique
EP3406363A4 (fr) Procédé de traitement de matage et dispositif de traitement de matage
EP3565357A4 (fr) Procédé et dispositif de traitement de demande de planification
EP4060526A4 (fr) Procédé et dispositif de traitement de texte
EP3598179A4 (fr) Capteur sismique et procédé de détermination de séisme
EP3413666A4 (fr) Procédé et dispositif de traitement de transmission
EP3647825A4 (fr) Capteur sismique et procédé de détermination de séisme
EP4032333A4 (fr) Procédé permettant de communiquer avec un appareil électronique externe et appareil électronique associé
EP3432036A4 (fr) Capteur sismique et procédé de détection de séisme
EP3540669A4 (fr) Procédé et dispositif de traitement de transaction
MA71748A (fr) Procédé sûr et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il12/il23
EP3897722A4 (fr) Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
EP3966774A4 (fr) Système et procédé de détection de fuite extérieure